For blood donation and component processing, Fresenius Kabi offers medical devices. These include cell separators (apheresis systems), autotransfusion devices, blood bag and filter systems as well as related blood processing equipment. Component processing consists of the separation and collection of certain blood cells.

Blood Cell Separator

The Fresenius cell separator has three areas of application:

• Donate blood cells: obtaining cells from the blood of a donor for transfusion, for example for treating coagulation dysfunctions or leukemia patients
• Remove cancer cells: removing diseased cells or blood plasma from the blood of a patient with leukemia or an autoimmune disease, i. e., in patients with disorders where the body produces defense substances against its own cells
• Collect a patient’s cells: collecting cells from a patient's own blood for re-infusion, for example prior to operation.

Blood bag systems

Blood bag systems are the foundation for worldwide blood supply by "classical" blood donation. More than 90 percent of all blood donations are processed in these systems that consist of up to six different bags with variable functions.

A combination of bags with venous cannulae and integrated needle protection, pre-donation sampling pouches and different filtration devices form the basis for highly professional whole blood collection systems. They allow producing different blood component preparations according to national and international standards. Blood donation and processing with these systems is supplemented by other devices such as automated scales and blood separators, sterile docking systems and sealers to name a few.

Comprehensive patient care begins with prevention. Fresenius Helios' occupational healthcare centers offer a wide range of workplace prevention services. In addition, the Helios Prevention Center (HPC) of Fresenius Helios offers programs for individual prevention and company health management in the form of checkups and health coaching at numerous locations around Germany.
 

Occupational Healthcare

The aim of effective occupational healthcare is to maintain and promote health, prevent harmful influences resulting from working life, detect illnesses and damage to health at an early stage, as well as reintegrate employees into the workplace after a longer period of absence due to illness.

In Germany, Helios offers fully comprehensive occupational medical care with a fixed, permanent contact person at 17 occupational healthcare centers. This covers everything from legally required examinations, health protection and promotion to risk assessments and recommendations for optimal workplace design.

Spain's leading occupational risk prevention companies Fraterprevención, MC Prevención, Premap and Unipresalud complement the Quirónsalud network, with more than 150 centers throughout Spain and a presence in Latin America and the Middle East.

 

Helios Prevention Center (HPC)

A check-up at the Helios Prevention Center provides an accurate picture of one's own state of health. Our participants at one of our six locations benefit from short waiting times, short distances and holistic lifestyle advice.

The HPC qualifies participants to handle health issues with confidence and enables them to achieve a performance grade that can function as a model. Health conscious and competent leadership can act as a beacon to bind together and motivate employees. HPC views itself as a partner to companies that want to actively promote the health of their employees. From a one-day checkup at a Helios clinic to health workshops lasting several days at beautifully situated resorts – our modular program combines Helios quality with the ambience of exclusive hotels. Studies show occupational healthcare measures generate outstanding cost-benefit ratios.

Fresenius Helios is the leading private healthcare provider in Europe serving with around 140 clinics and numerous outpatient facilities about 27 million people annually. Together with Fresenius Kabi, a provider of healthcare products for the critically and chronically ill, Fresenius Helios is part of the Fresenius healthcare group. With its 130,000 employees of the Helios Group in Germany and Quirónsalud in Spain and Latin America, Fresenius Helios generated total sales of more than 13.5 billion euros in 2025.

Helios Germany operates more than 80 hospitals, about 200 outpatient care centers with, six prevention centers and 30 occupational medicine centers. Helios treats approximately 5.6 million patients annually, of whom 4 million are outpatients. Since its beginnings, Helios has focused on measurable, high medical quality as well as data transparency and is better than the German average in more than 90 percent of the quality targets. With about 80,000 employees, Helios generated sales of €8.1 billion in 2025. With its own 35 training centers, Helios represents education and training in the healthcare sector. Helios Germany is headquartered in Berlin.

Quirónsalud has 57 hospitals, including seven in Latin America, around 130 outpatient centers and more than 300 occupational risk prevention centers, and treats approximately 22 million patients annually, of whom 20 million are outpatients. Quirónsalud has about 50,000 employees and generated sales of more than €5.4 billion in 2025. 

 

Fresenius is one of the top 40 companies in Germany in terms of market capitalization and is included in Germany's leading index, the DAX. We are also listed in the STOXX Europe 600 Health Care, the FTSEurofirst 300 and the DAXsector Pharma & Healthcare indices.

Fresenius ordinary shares are traded on the stock exchanges in Frankfurt, Düsseldorf and Munich.

At the end of July 2022, Fresenius SE & Co. KGaA's capital stock was 563,237,277 ordinary shares. The shares are notional no-par-value shares. Each share represents €1.00 of the capital stock.

 

Nutrition is a topic which is all around us, day by day. While we often talk about obesity and weight loss diets we actually overlook that the opposite, meaning mal- or undernutrition, can be as detrimental. We talk about malnutrition when our body is not provided with sufficient energy and nutrients over several days. These nutrients, for example protein, carbohydrates, fats, vitamins and minerals, are necessary to ensure all essential functions of the body.

When our nutritional status is not optimal our body will get w​eaker in its reaction towards challenges, such as a disease, a cold or an infection. Improving our nutritional status will therefore support and protect our body.

Enteral Nutrition

Every normal form of nutrition is actually enteral. The word, which comes from the Greek “enteron,” or intestines, means, “using the gastrointestinal tract.” Enteral nutrition therapies are designed for patients who cannot nourish themselves sufficiently but still have an adequate digestive function. It is therefore ideal for patients who experience problems chewing or swallowing, loss of appetite, suffer from neurological or gastro-intestinal diseases, or are unconscious. Enteral nutrition is administered via sip feeds or also tube feeds.

Parenteral Nutrition

Patients who are given Fresenius Kabi infusion solutions receive all the components of balanced nutrition: carbohydrates, amino acids and fats as well as minerals, vitamins and trace elements. The composition of these nutritional solutions can be precisely balanced to feed a patient for any period of time.

Parenteral nutrition is necessary when the stomach or intestine – for instance due to an illness or operation – can no longer perform their tasks. A doctor may also decide that a patient should receive parenteral nutrition prior to an operation or during lengthy examinations when he or she is not allowed to eat. In intravenous nutrition, all key nutrients enter the bloodstream as molecular components. A patient can rely on parenterally given nutrients for a long period of time.

There are a number of liquids with a variety of compositions that can be used for parenteral nutrition therapy either on their own or as a mixture. When deciding on the best nutritional therapy, the general condition of the patient plays an important role, as well as a patient’s age and weight. There are also solutions for patients with kidney or liver disease that contain a special composition of amino acids. Fresenius Kabi offers amino acids and carbohydrates as single components but also as a combination that contains both nutritional elements. Three-chamber bags contain all three important nutrients including fats.

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients. 

Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition portfolio includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, Fresenius Kabi offers vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more. 

Fresenius Kabi employs over 40,000 people worldwide. In 2025 the company reported sales of more than €8.5 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group and one of the two Operating Companies of Fresenius.

You will be now forwarded to the Fresenius Career page.

If the automatic redirect is not working, please click on the following link.

 

Fresenius Career

Fresenius Kabi has agreed to collaborate with Phlow Corporation, a public benefit company, to expand access to affordable sterile injectables formulated for U.S. children’s hospitals and to help strengthen the supply chain for U.S.-sourced API and essential medicines. The companies will work together to supply private-labelled products, co-develop and manufacture novel products and make essential medicines rapidly available in the event of a public health emergency.

Fresenius Kabi has agreed to collaborate with Phlow Corporation, a public benefit company, to expand access to affordable sterile injectables formulated for U.S. children’s hospitals and to help strengthen the supply chain for U.S.-sourced API and essential medicines. The companies will work together to supply private-labelled products, co-develop and manufacture novel products and make essential medicines rapidly available in the event of a public health emergency.

Ensure financial flexibility, maintain our investment grade rating, limit refinancing risks and optimize the cost of capital are the main objectives in Fresenius’s financing strategy.

To remain financially flexible, we maintain adequate liquidity headroom. We are committed to our investment grade rating, which provides us with advantages with respect to market access and funding costs.

Our refinancing risks are limited due to a balanced maturity profile that is characterized by a broad range of maturities with a high proportion of mid- and long-term debt up to 2034. Relevant financing instruments include bonds, Schuldschein Loans and bank loans. In addition, Fresenius maintains a commercial paper program. 

Another key objective of Fresenius’ financing strategy is to optimize the cost of capital by employing an adequate mix of equity and debt.

In 2025, deleveraging will remain a key priority. Fresenius has upgraded its leverage target corridor to 2.5 to 3.0x net debt/EBITDA (previously 3.5 to 3.0x). This allows us to stay financially flexible while solidifying our solid investment grade rating.
 

Fresenius Group

¹ Prior-year figures have been adjusted due to the deconsolidation of Fresenius Medical Care operations

² Before special items

³ At average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures, including lease liabilities, including Fresenius Medical Care dividend; Net debt adjusted for the valuation effect of the exchangeable bond